MX2021014892A - Composiciones y metodos para el tratamiento del dolor en sujetos con artritis reumatoide. - Google Patents

Composiciones y metodos para el tratamiento del dolor en sujetos con artritis reumatoide.

Info

Publication number
MX2021014892A
MX2021014892A MX2021014892A MX2021014892A MX2021014892A MX 2021014892 A MX2021014892 A MX 2021014892A MX 2021014892 A MX2021014892 A MX 2021014892A MX 2021014892 A MX2021014892 A MX 2021014892A MX 2021014892 A MX2021014892 A MX 2021014892A
Authority
MX
Mexico
Prior art keywords
rheumatoid arthritis
compositions
methods
treating pain
subj ects
Prior art date
Application number
MX2021014892A
Other languages
English (en)
Inventor
Stefano Fiore
Toshio Kimura
Susan Boklage
John Gregory St
Wenhui Wei
Vivian Bykerk
Original Assignee
Sanofi Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Biotechnology filed Critical Sanofi Biotechnology
Publication of MX2021014892A publication Critical patent/MX2021014892A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente divulgación se refiere al uso de un anticuerpo anti-receptor de IL6 para tratar un dolor inaceptable en sujetos con artritis reumatoide. Los sujetos con dolor inaceptable pueden tener, p. ej., dolor refractario o dolor refractario estricto.
MX2021014892A 2019-06-04 2020-06-03 Composiciones y metodos para el tratamiento del dolor en sujetos con artritis reumatoide. MX2021014892A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962857247P 2019-06-04 2019-06-04
US201962930966P 2019-11-05 2019-11-05
EP20305191 2020-02-27
PCT/US2020/035871 WO2020247461A1 (en) 2019-06-04 2020-06-03 Compositions and methods for treating pain in subj ects with rheumatoid arthritis

Publications (1)

Publication Number Publication Date
MX2021014892A true MX2021014892A (es) 2022-06-27

Family

ID=71842803

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021014892A MX2021014892A (es) 2019-06-04 2020-06-03 Composiciones y metodos para el tratamiento del dolor en sujetos con artritis reumatoide.

Country Status (14)

Country Link
US (1) US20200399380A1 (es)
EP (1) EP3980459A1 (es)
JP (1) JP2022534794A (es)
KR (1) KR20230061198A (es)
CN (1) CN115667301A (es)
AU (1) AU2020288561A1 (es)
BR (1) BR112021024445A2 (es)
CA (1) CA3142710A1 (es)
CO (1) CO2021017737A2 (es)
IL (1) IL288573A (es)
MA (1) MA56116A (es)
MX (1) MX2021014892A (es)
TW (1) TW202110892A (es)
WO (1) WO2020247461A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024526414A (ja) * 2022-04-06 2024-07-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｉｌ－６ｒアンタゴニストを投与することによってリウマチ性多発筋痛症を処置するための組成物および方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5215534A (en) 1991-12-02 1993-06-01 Lawrence De Harde Safety syringe system
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
WO2007013168A1 (ja) 2005-07-29 2007-02-01 Fujitsu Limited Ｒｆタグ及びｒｆタグを製造する方法
PL2041177T3 (pl) 2006-06-02 2012-09-28 Regeneron Pharma Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
US9427531B2 (en) 2010-06-28 2016-08-30 Sanofi-Aventis Deutschland Gmbh Auto-injector
US9248242B2 (en) 2012-04-20 2016-02-02 Safety Syringes, Inc. Anti-needle stick safety device for injection device
US20140155827A1 (en) 2012-12-03 2014-06-05 Mylan, Inc. Medicament information system and method
US20170252434A1 (en) * 2014-09-16 2017-09-07 Sanofi Biotechnology Compositions for improving the health related quality of life of rheumatoid arthritis patients

Also Published As

Publication number Publication date
CO2021017737A2 (es) 2022-05-20
US20200399380A1 (en) 2020-12-24
IL288573A (en) 2022-02-01
EP3980459A1 (en) 2022-04-13
AU2020288561A1 (en) 2021-12-23
JP2022534794A (ja) 2022-08-03
CN115667301A (zh) 2023-01-31
KR20230061198A (ko) 2023-05-08
CA3142710A1 (en) 2020-12-10
MA56116A (fr) 2022-04-13
BR112021024445A2 (pt) 2022-02-15
TW202110892A (zh) 2021-03-16
WO2020247461A1 (en) 2020-12-10

Similar Documents

Publication Publication Date Title
PH12020551932A1 (en) Methods of treating cancers and enhancing efficacy of t cell redirecting therapeutics
MX2019013072A (es) Formulaciones de anticuerpos anti-lag3 y coformulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1.
NZ743124A (en) Antibodies targeting fc receptor-like 5 and methods of use
PH12019502331A1 (en) Treatment of asthma with anti-tslp antibody
MX2018001532A (es) Anticuerpos anti-angptl8 y usos de estos.
PH12021550152A1 (en) Anti-cd112r compositions and methods
PH12020551671A1 (en) Chimeric receptors to dll3 and methods of use thereof
MX2020000342A (es) Anticuerpos agonistas que se unen a cd137 humano y sus usos.
SG10201804000TA (en) Compositions for the treatment of rheumatoid arthritis and methods of using same
MX2021005394A (es) Co-formulaciones de anticuerpos anti-gen de activacion de linfocitos 3 (anti-lag3) y anticuerpos anti-muerte programada-1 (anti-pd-1).
MY187975A (en) Antigen-binding proteins that activate the leptin receptor
MY196448A (en) Anti-Htra1 Antibodies and Methods of use Thereof
MX2023014841A (es) Composiciones para tratar artritis reumatoide.
MX2024001909A (es) Metodos y composiciones para el diagnostico y el tratamiento de trastornos en pacientes con elevados niveles de cxcl9 y otros biomarcadores.
CR20220329A (es) Anticuerpos anti–mertk y metodos de uso de los mismos
IL282375A (en) For the delay and treatment of synucleopathy, tauopathy and other diseases 2,3,5-TRIMETHYL-6-NONYLCYCLOHEXA-2,5-DIENE-1,4-DIONE
MX2021012692A (es) Anticuerpos anti-mertk y sus metodos de uso.
WO2017136834A8 (en) Methods of differentiating stem cell-derived ectodermal lineage precursors
MX2018001849A (es) Metodos y composiciones que usan bifidobacterium longum para modular la reactividad emocional y tratar o prevenir perturbaciones subclinicas del estado de animo.
IL280824A (en) Methods and compositions for the treatment of rheumatoid arthritis patients
MX2021014892A (es) Composiciones y metodos para el tratamiento del dolor en sujetos con artritis reumatoide.
MX2023006777A (es) Composiciones y métodos que comprenden antagonistas de proteína 2 relacionada con frizzled secretada (sfrp2).
MX2021012969A (es) Metodos de diagnostico y tratamiento de la artritis reumatoide.
MX2021001877A (es) Composiciones y métodos para el tratamiento de lesión pulmonar aguda.
MX2022015030A (es) Composiciones y metodos para el tratamiento del dolor no inflamatorio en sujetos con artritis reumatoide.